SCHEMBL1677264

SCHEMBL1677264

CCOC(=O)/C(C)=N\Nc1ccc(Oc2ccc(S(C)(=O)=O)cn2)cc1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 5/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
PDE4B Q07343 1/20 0.35
ADAMTS4 O75173 1/20 0.34
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP13 P45452 1/20 0.34
MMP14 P50281 1/20 0.34
ADAMTS5 Q9UNA0 1/20 0.34
P2RX3 P56373 2/20 0.34
ACACB O00763 2/20 0.34
ACACA Q13085 1/20 0.34
KDR P35968 2/20 0.34
BRAF P15056 1/20 0.34
MEN1 O00255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12807186 1.00 ALDH1A1 (0.39) ALDH1A1HTTNPSR1MAPTKDM4E
SCHEMBL1082996 1.00 ALDH1A1 (0.39) ALDH1A1HTTNPSR1MAPTKDM4E
SCHEMBL1677556 0.88 ALDH1A1 (0.38) ALDH1A1HTTNPSR1MAPTKDM4E
SCHEMBL1083112 0.88 ALDH1A1 (0.38) ALDH1A1HTTNPSR1MAPTKDM4E
SCHEMBL15576381 0.88 ALDH1A1 (0.38) ALDH1A1HTTNPSR1MAPTKDM4E
SCHEMBL4305687 0.88 ALDH1A1 (0.38) ALDH1A1HTTNPSR1MAPTKDM4E
SCHEMBL12734156 0.88 PPARG (0.39) MAPTKDM4ENPC1RAB9APDE4B
SCHEMBL12734234 0.87 MAPT (0.36) ALDH1A1HTTNPSR1MAPTNPC1
SCHEMBL1677768 0.87 MAPT (0.36) ALDH1A1HTTNPSR1MAPTNPC1
SCHEMBL1677766 0.87 MAPT (0.36) ALDH1A1HTTNPSR1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673942-B2 Fused ring compounds and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-18 US disclosed
US-20110098297-A1 FUSED RING COMPOUNDS AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098297-A1 FUSED RING COMPOUNDS AND USE THEREOF GCKR, GPR119, SLC5A1 ALDH1A1 305/4885HTT 2320/4885NPSR1 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.